Moderna, Inc. (NASDAQ:MRNA - Get Free Report) Director Noubar Afeyan sold 15,000 shares of the stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $110.92, for a total value of $1,663,800.00. Following the sale, the director now directly owns 2,026,931 shares in the company, valued at $224,827,186.52. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Noubar Afeyan also recently made the following trade(s):
- On Wednesday, April 24th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $108.32, for a total value of $1,624,800.00.
- On Wednesday, April 17th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $103.38, for a total value of $1,550,700.00.
- On Wednesday, April 10th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $107.12, for a total transaction of $1,606,800.00.
- On Wednesday, April 3rd, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $101.68, for a total transaction of $1,525,200.00.
- On Wednesday, March 27th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $109.06, for a total transaction of $1,635,900.00.
- On Wednesday, March 20th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $102.39, for a total value of $1,535,850.00.
- On Wednesday, March 13th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $108.54, for a total value of $1,628,100.00.
Moderna Price Performance
The most important AI company you've never heard of
From Manward Press | Ad
Because this small company solves the BIGGEST problem with Nvidia's AI chips.
Already, Amazon, Microsoft, Google and others are lining up to get this company's products.
Get the full story on this secret AI company poised for massive growth
Shares of NASDAQ:MRNA opened at $125.00 on Friday. Moderna, Inc. has a 52-week low of $62.55 and a 52-week high of $142.79. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.36 and a current ratio of 4.03. The business has a fifty day moving average of $105.05 and a two-hundred day moving average of $94.37.
Moderna (NASDAQ:MRNA - Get Free Report) last announced its quarterly earnings data on Thursday, May 2nd. The company reported ($3.07) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($3.59) by $0.52. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The firm had revenue of $167.00 million during the quarter, compared to analyst estimates of $93.26 million. During the same quarter in the prior year, the firm posted $0.19 earnings per share. Moderna's quarterly revenue was down 91.0% on a year-over-year basis. As a group, sell-side analysts predict that Moderna, Inc. will post -7.51 EPS for the current fiscal year.
Institutional Trading of Moderna
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in Moderna by 22.6% in the 4th quarter. Vanguard Group Inc. now owns 33,907,072 shares of the company's stock valued at $3,372,058,000 after buying an additional 6,248,623 shares during the period. Wellington Management Group LLP raised its stake in shares of Moderna by 28.8% in the 4th quarter. Wellington Management Group LLP now owns 7,225,579 shares of the company's stock valued at $718,584,000 after acquiring an additional 1,614,460 shares during the period. The Manufacturers Life Insurance Company lifted its holdings in shares of Moderna by 77.3% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 3,876,147 shares of the company's stock worth $400,367,000 after acquiring an additional 1,690,341 shares during the last quarter. Norges Bank purchased a new position in shares of Moderna during the 4th quarter worth approximately $347,565,000. Finally, Invesco Ltd. increased its holdings in Moderna by 19.8% in the 3rd quarter. Invesco Ltd. now owns 3,126,028 shares of the company's stock valued at $322,887,000 after purchasing an additional 517,683 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company's stock.
Analysts Set New Price Targets
A number of research firms have recently commented on MRNA. Canaccord Genuity Group boosted their price objective on Moderna from $91.00 to $106.00 and gave the company a "hold" rating in a research report on Friday. William Blair restated a "market perform" rating on shares of Moderna in a research report on Monday, April 1st. Oppenheimer lifted their target price on shares of Moderna from $142.00 to $163.00 and gave the company an "outperform" rating in a research report on Friday. Royal Bank of Canada upped their price target on shares of Moderna from $125.00 to $135.00 and gave the stock an "outperform" rating in a research report on Friday. Finally, Jefferies Financial Group reiterated a "buy" rating and issued a $125.00 price objective on shares of Moderna in a report on Tuesday, April 9th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have issued a buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $129.55.
Read Our Latest Analysis on Moderna
Moderna Company Profile
(
Get Free Report)
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
